Company Overview and News

[Press] Shale Gas Hydraulic Fracturing Market will Exhibit a Steady 9.8% CAGR through 2027

2018-04-13 oilvoice
Future Market Insights assesses the shale gas hydraulic fracturing market in the U.S, Canada, and China in its newly published report titled, “Shale Gas Hydraulic Fracturing Market: Canada, US, and China Industry Analysis 2012–2016 and Opportunity Assessment 2017–2027.” According to the report, the US market production value is anticipated to expand from 18,059 BCF (2017) at a 9.8% CAGR, Canadian market's production volume of 213.

Canadian Solar Wins 3 Solar PV Projects From Brazil Auction

2018-04-12 zacks
Canadian Solar Inc. (CSIQ - Free Report) recently clinched three solar photovoltaic (PV) projects in Brazil's A-4 auction. The auction, held on April 4, 2018, made Canadian Solar the only company to successfully win projects in all of the five Federal Auctions held in Brazil, to date. Details of the Deal The three solar PV projects totaling 364 megawatts-peak (MWp) are located in the states of Minas Gerais and Ceara.

New Strong Buy Stocks for April 10th

2018-04-10 zacks
ArcelorMittal (MT - Free Report) : This company that owns and operates steel manufacturing and mining facilities has seen the Zacks Consensus Estimate for its current year earnings increasing 5.9% over the last 60 days.

What to Expect for CNX Midstream Partners

CNX Midstream Partners (CNXM) has risen nearly 7% in 2018. So far, the company has outperformed many of its MLP peers. CNX Midstream Partners, earlier known as “CONE Midstream Partners,” is owned by CNX Resources (CNX). Notably, CONSOL Energy separated its gas and coal business into two independent companies in November 2017. Now, the gas business trades as “CNX Resources.”

BHP Billiton upgraded to sector perform from underperform at RBC Capital

2018-04-04 marketwatch
LONDON -- Glencore PLC added to its growing portfolio of coal assets with a $1.7 billion investment in a pair of Australian producers -- part of a bet by the mining giant that demand for coal in Southeast Asia will remain strong, even as competitors shy away from the stuff.

Appalachia Is Driving the Rise in US Natural Gas Proved Reserves

The United States has been the world’s top producer of natural gas since 2009, when its production surpassed Russia’s, with growth increasingly coming from Appalachia, especially the Marcellus and Utica shales, in recent years.

Why You Should Invest In Consol Energy

2018-04-03 seekingalpha
Consol Energy is generating free cash flow of ~$250 million per year, yet the entire company is being valued at $800 million.


CNX Center 1000 CONSOL Energy Drive

CNX / CONSOL Energy, Inc. 8-K/A (Current Report)


CNX / CONSOL Energy, Inc. 8-K (Current Report)


CNX / CONSOL Energy, Inc. FORM 8-K (Current Report)


CNX / CONSOL Energy, Inc. 8-K (Current Report)


Why Consol Coal Resources' 14% Dividend Is Solid

2018-03-14 seekingalpha
CCR is a coal MLP trading at a deep discount to comps in spite of having a better balance sheet.

CNX / CONSOL Energy, Inc. 8-K (Current Report)


Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 20854P109